JP2024534420A - 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 - Google Patents

環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 Download PDF

Info

Publication number
JP2024534420A
JP2024534420A JP2024516798A JP2024516798A JP2024534420A JP 2024534420 A JP2024534420 A JP 2024534420A JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024534420 A JP2024534420 A JP 2024534420A
Authority
JP
Japan
Prior art keywords
alkyl
pharma
stereoisomer
tautomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516798A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023043923A5 (https=
JP2024534420A5 (https=
Inventor
ビー. ピンカートン,アンソニー
モーガー,ジャック
ファム ホン チュオン,イエン
ジャネット エルスドン,レイチェル
トッド マイヤー,ステファン
Original Assignee
バウンドレス バイオ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バウンドレス バイオ,インク. filed Critical バウンドレス バイオ,インク.
Publication of JP2024534420A publication Critical patent/JP2024534420A/ja
Publication of JPWO2023043923A5 publication Critical patent/JPWO2023043923A5/ja
Publication of JP2024534420A5 publication Critical patent/JP2024534420A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024516798A 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 Pending JP2024534420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
US63/245,718 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2024534420A true JP2024534420A (ja) 2024-09-20
JPWO2023043923A5 JPWO2023043923A5 (https=) 2025-08-07
JP2024534420A5 JP2024534420A5 (https=) 2025-08-07

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516798A Pending JP2024534420A (ja) 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用

Country Status (11)

Country Link
US (1) US20250002486A1 (https=)
EP (1) EP4401728A4 (https=)
JP (1) JP2024534420A (https=)
KR (1) KR20240101555A (https=)
CN (1) CN118434417A (https=)
AU (1) AU2022345092A1 (https=)
CA (1) CA3231660A1 (https=)
IL (1) IL311458A (https=)
MX (1) MX2024003258A (https=)
TW (1) TW202328121A (https=)
WO (1) WO2023043923A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021325905A1 (en) 2020-08-12 2023-04-13 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ,インク. 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
WO2025049814A2 (en) * 2023-09-01 2025-03-06 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3466934T (pt) * 2016-05-31 2024-04-30 Taiho Pharmaceutical Co Ltd Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
US20200405697A1 (en) * 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent
MX2020005478A (es) * 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
US20220226291A1 (en) * 2019-05-29 2022-07-21 Taiho Pharmaceutical Co., Ltd. Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator
US20240158383A1 (en) * 2021-03-02 2024-05-16 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2022345092A1 (en) 2024-04-04
EP4401728A4 (en) 2025-08-06
MX2024003258A (es) 2024-04-05
EP4401728A1 (en) 2024-07-24
WO2023043923A1 (en) 2023-03-23
CA3231660A1 (en) 2023-03-23
IL311458A (en) 2024-05-01
KR20240101555A (ko) 2024-07-02
CN118434417A (zh) 2024-08-02
TW202328121A (zh) 2023-07-16
US20250002486A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
JP2024520481A (ja) チェックポイントキナーゼ1(chk1)阻害剤およびその使用
JP2025522294A (ja) ピリジンチェックポイントキナーゼ1(chk1)阻害剤及びその使用
WO2024118564A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
JP2024534420A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
EA021126B1 (ru) Замещенные изохинолиноны и хинализолиноны
TW200906818A (en) Chemical compounds
JP7678929B2 (ja) ピリジノンmk2阻害剤及びその使用
WO2022187200A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2024534421A (ja) スルファミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
JP2024516359A (ja) Ulk1/2阻害剤およびその使用
WO2024118596A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
JP2025531147A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
EA051928B1 (ru) Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250730